| 1 |
35413091 | Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells. | 2022 |
1 |
| 2 |
33301843 | Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells. | 2021 Jan |
2 |
| 3 |
33472956 | Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. | 2021 Jan 20 |
2 |
| 4 |
33529438 | Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells. | 2021 Aug |
1 |
| 5 |
31789403 | Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1. | 2020 Feb |
4 |
| 6 |
32277442 | A comparative molecular analysis of DNA damage response, cell cycle progression, viability and apoptosis of malignant granulosa cells exposed to gemcitabine and cisplatin. | 2020 May |
1 |
| 7 |
32579780 | The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. | 2020 Oct |
3 |
| 8 |
32647134 | Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer. | 2020 Aug |
1 |
| 9 |
33261142 | Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer. | 2020 Nov 27 |
1 |
| 10 |
30573684 | Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe. | 2019 Feb 8 |
2 |
| 11 |
31044505 | Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. | 2019 Jul |
2 |
| 12 |
31444271 | The DNA repair helicase RECQ1 has a checkpoint-dependent role in mediating DNA damage responses induced by gemcitabine. | 2019 Oct 18 |
2 |
| 13 |
31783584 | ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1. | 2019 Nov 27 |
1 |
| 14 |
29115606 | DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells. | 2018 Jan |
1 |
| 15 |
29286153 | CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. | 2018 Mar |
2 |
| 16 |
29735549 | Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine. | 2018 Jun 1 |
1 |
| 17 |
29895190 | The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors. | 2018 |
2 |
| 18 |
30420613 | SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance. | 2018 Nov |
1 |
| 19 |
27815358 | Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. | 2017 May 15 |
1 |
| 20 |
28049532 | Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. | 2017 Jan 3 |
2 |
| 21 |
28978069 | Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor. | 2017 Sep 15 |
3 |
| 22 |
29048622 | Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells. | 2017 Nov |
1 |
| 23 |
29118324 | Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine. | 2017 Nov 8 |
4 |
| 24 |
29152060 | Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine. | 2017 Oct 20 |
3 |
| 25 |
26612134 | LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. | 2016 Feb |
5 |
| 26 |
26872382 | The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11. | 2016 Mar 29 |
1 |
| 27 |
26890478 | Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry. | 2016 |
3 |
| 28 |
27123146 | Synergistic antitumor activity of gemcitabine combined with triptolide in pancreatic cancer cells. | 2016 May |
1 |
| 29 |
27272773 | Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines. | 2016 Jun |
1 |
| 30 |
27634334 | DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. | 2016 Sep 15 |
1 |
| 31 |
25349305 | Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. | 2015 Jan |
2 |
| 32 |
25594740 | Identification of novel aminothiazole and aminothiadiazole conjugated cyanopyridines as selective CHK1 inhibitors. | 2015 Mar 6 |
1 |
| 33 |
25774168 | Targeting lung cancer through inhibition of checkpoint kinases. | 2015 |
1 |
| 34 |
25952464 | Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. | 2015 Aug |
2 |
| 35 |
25965828 | Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress. | 2015 May 30 |
2 |
| 36 |
26141863 | CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus. | 2015 Sep 1 |
1 |
| 37 |
26462050 | A novel assay revealed that ribonucleotide reductase is functionally important for interstrand DNA crosslink repair. | 2015 Nov 1 |
1 |
| 38 |
24114124 | Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. | 2014 Apr |
1 |
| 39 |
24247149 | Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death. | 2014 |
1 |
| 40 |
24448638 | Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. | 2014 Mar |
1 |
| 41 |
24556918 | The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells. | 2014 |
1 |
| 42 |
24838526 | Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. | 2014 Jun 15 |
1 |
| 43 |
24996846 | γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments. | 2014 Jul 4 |
2 |
| 44 |
23200172 | Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. | 2013 Mar 15 |
1 |
| 45 |
23483975 | A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. | 2013 |
7 |
| 46 |
23548269 | ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. | 2013 Jun 15 |
1 |
| 47 |
23593991 | The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. | 2013 Sep |
2 |
| 48 |
23687379 | Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine. | 2013 Aug 1 |
1 |
| 49 |
23873850 | Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. | 2013 Oct |
3 |
| 50 |
23892959 | Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. | 2013 Sep |
1 |